Lars Wallentin

ORCID: 0000-0003-0378-6531 · 4 papers in corpus
article 1986
Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate
·doi:10.1016/s0015-0282(16)49277-0

Ten women with endometriosis were treated with medroxyprogesterone acetate (MPA), 150 mg intramuscularly every second week. After 2 weeks, there was a significant (8%) decrease in the high-density lipoprotein (HDL) concentration. This reduc…

article 1986
Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate.
Fertility and Sterility

Ten women with endometriosis were treated with medroxyprogesterone acetate (MPA), 150 mg intramuscularly every second week. After 2 weeks, there was a significant (8%) decrease in the high-density lipoprotein (HDL) concentration. This reduc…

article 1984
Plasma lipoproteins during and after danazol treatment
Acta obstetricia et gynecologica Scandinavica. Supplement ·doi:10.3109/00016348409157000

Twelve women with pelvic endometriosis were treated with danazol, at a dose of 200 mg three times daily, over a 24-week period. The concentrations of cholesterol and triglycerides were determined in plasma and in the lipoprotein fractions. …

article 1984
Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women
Fertility and Sterility ·doi:10.1016/s0015-0282(16)47957-4

Twelve women with pelvic endometriosis were treated with 600 mg of danazol daily for 24 weeks. The molar and fractional lecithin:cholesterol acyl transfer (LCAT) rates and the concentrations of cholesterol, phospholipids, and triglycerides …